Tin tức & Cập nhật

Shorter antibiotic regimen enough in kids with pneumonia?
Shorter antibiotic regimen enough in kids with pneumonia?
10 Mar 2022 bởiRoshini Claire Anthony

Children with non-severe community-acquired pneumonia (CAP) may benefit from a 5-day antibiotic regimen compared with the current standard regimen of 10 days, according to results of the US-based SCOUT-CAP trial.

Shorter antibiotic regimen enough in kids with pneumonia?
10 Mar 2022
Delamanid-based regimens work against multidrug-resistant tuberculosis
Delamanid-based regimens work against multidrug-resistant tuberculosis
10 Mar 2022

The use of delamanid-containing regimens is safe and effective in the management of multidrug-resistant tuberculosis (MDR-TB), with high culture conversion and treatment success rates despite extensive resistance patterns, according to the results of a meta-analysis.

Delamanid-based regimens work against multidrug-resistant tuberculosis
10 Mar 2022
Continuing enzalutamide after progression improves PFS in mCRPC
Continuing enzalutamide after progression improves PFS in mCRPC
09 Mar 2022 bởiRoshini Claire Anthony

In patients with metastatic castration-resistant prostate cancer (mCRPC) who experience disease progression while on enzalutamide treatment, continuing enzalutamide appears to improve progression-free survival (PFS), according to results of the phase IIIb PRESIDE trial.

Continuing enzalutamide after progression improves PFS in mCRPC
09 Mar 2022
Use of alternative medicine not uncommon in melanoma patients
Use of alternative medicine not uncommon in melanoma patients
09 Mar 2022

About one in four cutaneous melanoma patients use at least one type of complementary and alternative medicine (CAM), of which herbs and turmeric are the most popular, reveals a prospective study from a tertiary cancer centre in Turkey.

Use of alternative medicine not uncommon in melanoma patients
09 Mar 2022
Immune-related adverse events portend better prognosis in ICI-treated hepatocellular carcinoma
Immune-related adverse events portend better prognosis in ICI-treated hepatocellular carcinoma
08 Mar 2022 bởiJairia Dela Cruz

Among advanced hepatocellular carcinoma patients being treated with immune checkpoint inhibitors (ICIs), the occurrence of multisystem and more severe immune-related adverse events is a favourable signal, being associated with survival advantage, according to a Singapore study.

Immune-related adverse events portend better prognosis in ICI-treated hepatocellular carcinoma
08 Mar 2022